Research location

Muncie

Indiana, United States

Published trials198

Site observations204

Linked trials published198

Page1 / 4

Research activity in Muncie

Indiana, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 198 trials and 204 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Muncie

198 linked trials · page 1 of 4

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsNCT07797335 · 2026-08-24 · 1 site observation

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)NCT07759245 · 2026-08-07 · 1 site observation

Gut, Immune, and Vascular Health in Metabolically Healthy ObesityNCT07559227 · 2026-03-01 · 1 site observation

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation

Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity PhenotypesNCT07095426 · 2025-05-20 · 1 site observation

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung CancerNCT06801834 · 2025-04-04 · 1 site observation

Effects of Body Composition on Vascular Health in Females With a Healthy Body WeightNCT06818500 · 2024-09-01 · 1 site observation

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionNCT06307652 · 2024-04-12 · 1 site observation

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)NCT05489211 · 2022-09-06 · 1 site observation

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerNCT03723928 · 2018-09-17 · 1 site observation

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNCT07861100 · 2026-10-26 · 1 site observation

NOT_YET_RECRUITING

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityNCT06693843 · 2024-10-28 · 1 site observation

Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on TirzepatideNCT06484114 · 2024-09-01 · 1 site observation

ACTIVE_NOT_RECRUITING

Postprandial Effects of Animal Versus Plant-Based ProteinNCT06445296 · 2023-11-01 · 1 site observation

A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940 · 2023-08-09 · 1 site observation

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · 2023-04-03 · 1 site observation

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05536804 · 2023-02-08 · 1 site observation

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide AcetateNCT05605964 · 2023-01-28 · 1 site observation

A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)NCT05662332 · 2023-01-14 · 1 site observation

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerNCT04975308 · 2021-10-04 · 1 site observation

ACTIVE_NOT_RECRUITING

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)NCT04636814 · 2021-07-12 · 1 site observation

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss ProgramNCT04657016 · 2021-03-29 · 1 site observation

Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 DiabetesNCT04419779 · 2021-03-08 · 1 site observation

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating MutationsNCT04639219 · 2020-12-30 · 1 site observation

ACTIVE_NOT_RECRUITING

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing TumorsNCT04482309 · 2020-08-18 · 1 site observation

ACTIVE_NOT_RECRUITING

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)NCT04428151 · 2020-08-06 · 1 site observation

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerNCT04092283 · 2020-04-29 · 1 site observation

ACTIVE_NOT_RECRUITING

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)NCT03988634 · 2019-06-29 · 1 site observation

A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesNCT03914326 · 2019-06-17 · 1 site observation

Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung CancerNCT03913455 · 2019-06-06 · 1 site observation

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · 2018-10-24 · 1 site observation

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerNCT03488693 · 2018-10-16 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyNCT03703297 · 2018-09-27 · 1 site observation

ACTIVE_NOT_RECRUITING

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic TrialNCT03596450 · 2018-07-13 · 3 site observations

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)NCT03521934 · 2018-06-15 · 1 site observation

Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung CancerNCT03382561 · 2018-05-21 · 1 site observation

ANTHEM-HFrEF Pivotal StudyNCT03425422 · 2018-05-01 · 1 site observation

Study to Investigate CSL112 in Subjects With Acute Coronary SyndromeNCT03473223 · 2018-03-21 · 1 site observation

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]NCT03265145 · 2017-09-20 · 1 site observation

Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart FailureNCT03035474 · 2017-04-21 · 1 site observation

Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy RegistryNCT03075215 · 2017-04-14 · 1 site observation

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)NCT03043872 · 2017-03-27 · 1 site observation

ACTIVE_NOT_RECRUITING

Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-StudyNCT03037931 · 2017-03-15 · 1 site observation

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 InhibitorNCT03041181 · 2017-01-27 · 1 site observation

A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 DiabetesNCT02692716 · 2017-01-17 · 1 site observation

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyNCT02927249 · 2017-01-06 · 1 site observation

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329 · 2017-01-06 · 1 site observation

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MINCT02924727 · 2016-12-09 · 1 site observation

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.NCT02849080 · 2016-09-20 · 1 site observation

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise OnlyNCT02906930 · 2016-09-20 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.